Press Releases
Updates on ProBioGen and currently relevant topics on human biopharmaceuticals, notably on therapeutic proteins and viral vaccines.
ProBioGen’s DirectedLuck™ Transposase Licensed by TOP15 Global BioPharma Company
Berlin, Germany, September 28, 2021: ProBioGen today announced the closing of a DirectedLuck Transposase Technology research license agreement with another global biopharma..
Nobelpharma signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX®
Berlin, Germany, August 12, 2021: ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to..
ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®
Berlin, Germany and Bethesda, MD, USA, July 27, 2021: ProBioGen and ValenzaBio today jointly announced the initiation of a cell line development project involving the application..
Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line
Berlin, Germany, July 13, 2021: ProBioGen announced today that they have entered into a research license agreement with Heat Biologics for both ProBioGen's Transposase System..
ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific
Berlin, Germany and Utrecht, Netherlands, June 22, 2021: ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a..
City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform
Berlin, Germany and Duarte, USA, June 9, 2021: ProBioGen AG has announced a commercial product license agreement with City of Hope, a world-renowned independent research and..
ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company
Berlin, Germany and Cairo, Egypt, May 27, 2021: ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin..
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
Apr 12, 2023
Press Contact
ProBioGen News
Join our news and always be up-to-date.